The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: The emerging role of adipokines

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Palios, John ^a   Kadoglou, Nikolaos P E ^a   Lampropoulos, Stylianos ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Department of Cardiology   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANTIRETROVIRUS AGENT; APELIN; ATORVASTATIN; FLUINDOSTATIN; INSULIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PRAVASTATIN; ROSUVASTATIN; VASPIN;

BODY FAT; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PULSE WAVE; REVIEW; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; FEMALE; MALE; METABOLISM;

ADIPOKINES; ADIPOSE TISSUE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; WAIST CIRCUMFERENCE;

EID: 84855583565     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/103063     Document Type: Review

References (77)

1. Palella F. J. Jr., Delaney K. M., Moorman A. C., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators Respiratory Care 1998 43 7 544 (Pubitemid 128751297)
2. Guaraldi G., Stentarelli C., Zona S., Orlando G., Carli F., Ligabue G., Lattanzi A., Zaccherini G., Rossi R., Modena M. G., Alexopoulos N., Palella F., Raggi P., Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects Atherosclerosis 2010 208 1 222 227
3. Grinspoon S., Carr A., Cardiovascular risk and body-fat abnormalities in HIV-infected adults The New England Journal of Medicine 2005 352 1 48 62 (Pubitemid 40075680)
4. Friis-Moller N., Sabin C. A., Weber R., Combination antiretroviral therapy and the risk of myocardial infarction The New England Journal of Medicine 2003 349 21 1993 2003
5. Charakida M., Donald A. E., Green H., Storry C., Clapson M., Caslake M., Dunn D. T., Halcox J. P., Gibb D. M., Klein N. J., Deanfield J. E., Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy Circulation 2005 112 1 103 109 (Pubitemid 40962575)
6. Hsue P. Y., Hunt P. W., Wu Y., Schnell A., Ho J. E., Hatano H., Xie Y., Martin J. N., Ganz P., Deeks S. G., Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients AIDS 2009 23 15 2021 2027
7. Lekakis J., Tsiodras S., Ikonomidis I., Palios J., Poulakou G., Rallidis L., Antoniadou A., Panagopoulos P., Papadopoulos A., Giamarellou H., Kremastinos D. T., HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease Clinical Science 2008 115 5-6 189 196
8. Thomas C. M., Smart E. J., How HIV protease inhibitors promote atherosclerotic lesion formation Current Opinion in Lipidology 2007 18 5 561 565 (Pubitemid 47462210)
9. Coll B., Parra S., Alonso-Villaverde C., Aragones G., Montero M., Camps J., Joven J., Masana L., The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection Stroke 2007 38 9 2477 2484 (Pubitemid 47329625)
10. Mondy K. E., Determinants of endothelial function in human immunodeficiency virus infection: a complex interplay among therapy, disease, and host factors Journal of The Cardiometabolic Syndrome 2008 3 2 88 92
11. Kaplan R. C., Kingsley L. A., Gange S. J., Benning L., Jacobson L. P., Lazar J., Anastos K., Tien P. C., Sharrett A. R., Hodis H. N., Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men AIDS 2008 22 13 1615 1624
12. Francisci D., Giannini S., Baldelli F., Leone M., Belfiori B., Guglielmini G., Malincarne L., Gresele P., HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction AIDS 2009 23 5 589 596
13. Hsue P. Y., Hunt P. W., Schnell A., Kalapus S. C., Hoh R., Ganz P., Martin J. N., Deeks S. G., Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis AIDS 2009 23 9 1059 1067
14. Trayhurn P., Wood I. S., Adipokines: inflammation and the pleiotropic role of white adipose tissue British Journal of Nutrition 2004 92 3 347 355 (Pubitemid 40277057)
15. Behrens G. M., Stoll M., Schmidt R. E., Lipodystrophy syndrome in HIV infection. What is it, what causes it and how can it be managed? Drug Safety 2000 23 1 57 76 (Pubitemid 30455917)
16. Jerico C., Knobel H., Montero M., Ordoez-Llanos J., Guelar A., Gimeno J. L., Saballs P., Lopez-Colomes J. L., Pedro-Botet J., Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors Diabetes Care 2005 28 1 132 137 (Pubitemid 40095795)
17. Miller J., Carr A., Emery S., Law M., Mallal S., Baker D., Smith D., Kaldor J., Cooper D. A., HIV lipodystrophy: prevalence, severity and correlates of risk in Australia HIV Medicine 2003 4 3 293 301 (Pubitemid 36949887)
18. Resino S., Micheloud D., Lorente R., Bellon J., Navarro M., Munoz-Fernandez M., Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy HIV Medicine 2011 12 1 54 60
19. European Paediatric Lipodystrophy Group, Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe AIDS 2004 18 10 1443 1451
20. Leow M. K., Addy C. L., Mantzoros C. S., Clinical review 159human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies Journal of Clinical Endocrinology and Metabolism 2003 88 5 1961 1976 (Pubitemid 36549862)
21. Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., D'Arminio Monforte A., Pradier C., Morfeldt L., Mateu S., Law M., El-Sadr W., De Wit S., Sabin C. A., Phillips A. N., Lundgren J. D., Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study AIDS 2003 17 8 1179 1193 (Pubitemid 36667761)
22. Periard D., Telenti A., Sudre P., Cheseaux J.-J., Halfon P., Reymond M. J., Marcovina S. M., Glauser M. P., Nicod P., Darioli R., Mooser V., Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The swiss HIV cohort study Circulation 1999 100 7 700 705 (Pubitemid 29383638)
23. Liang J. S., Distler O., Cooper D. A., Jamil H., Deckelbaum R. J., Ginsberg H. N., Sturley S. L., HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia Nature Medicine 2001 7 12 1327 1331 (Pubitemid 34007937)
24. Purnell J. Q., Zambon A., Knopp R. H., Pizzuti D. J., Achari R., Leonard J. M., Locke C., Brunzell J. D., Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects AIDS 2000 14 1 51 57 (Pubitemid 30072077)
25. Ranganathan S., Kern P. A., The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes Journal of Endocrinology 2002 172 1 155 162 (Pubitemid 34082954)
26. Reeds D. N., Mittendorfer B., Patterson B. W., Powderly W. G., Yarasheski K. E., Klein S., Alterations in lipid kinetics in men with HIV-dyslipidemia American Journal of Physiology 2003 285 3 48-3 E490 E497
27. Dube M. P., Stein J. H., Aberg J. A., Fichtenbaum C. J., Gerber J. G., Tashima K. T., Henry W. K., Currier J. S., Sprecher D., Glesby M. J., Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV medicine association of the infectious disease society of America and the adult AIDS clinical trials group Clinical Infectious Diseases 2003 37 5 613 627 (Pubitemid 37100800)
28. Van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., Cahn P., Lalloo U. G., Van Der Westhuizen I. P., Malan D. R., Johnson M. A., Santos B. R., Mulcahy F., Wood R., Levi G. C., Reboredo G., Squires K., Cassetti I., Petit D., Raffi F., Katlama C., Murphy R. L., Horban A., Dam J. P., Hassink E., Van Leeuwen R., Robinson P., Wit F. W., Lange J. M. A., Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study The Lancet 2004 363 9417 1253 1263 (Pubitemid 38496486)
29. Meininger G., Hadigan C., Laposata M., Brown J., Rabe J., Louca J., Aliabadi N., Grinspoon S., Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution Metabolism 2002 51 2 260 266 (Pubitemid 34168243)
30. Anderson O., Haugaard S. B., Andersen U. B., Friis-Moller N., Storgaard H., Volund A., Nielsen J. O., Iversen J., Madsbad S., Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in -cell function Metabolism 2003 52 10 1343 1353 (Pubitemid 37351104)
31. Haugaard S. B., Andersen O., Storgaard H., Dela F., Holst J. J., Iversen J., Nielsen J. O., Madsbad S., Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of -cells American Journal of Physiology 2004 287 4 E677 E685
32. Kino T., Gragerov A., Slobodskaya O., Tsopanomichalou M., Chrousos G. P., Pavlakis G. N., Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators Journal of Virology 2002 76 19 9724 9734 (Pubitemid 35006513)
33. Shrivastav S., Kino T., Chrousos G. P., Kopp J. B., HIV-1 Vpr binds and inhibits PPAR-gamma: implications for HIV-associated insulin resistance and lipodystroph Proceedings of the International Meeting of the Institute of Human Virology 2000 Baltimore, Md, USA
34. Kino T., De Martino M. U., Charmandari E., Ichijo T., Outas T., Chrousos G. P., HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients Diabetes 2005 54 1 23 31 (Pubitemid 40105091)
35. Lekakis J., Ikonomidis I., Palios J., Tsiodras S., Karatzis E., Poulakou G., Rallidis L., Antoniadou A., Panagopoulos P., Papadopoulos A., Triantafyllidi H., Giamarellou H., Kremastinos D. T., Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus American Journal of Hypertension 2009 22 8 828 834
36. Beasley J. M., Ange B. A., Anderson C. A., Characteristics associated with fasting appetite hormones (obestatin, ghrelin, and leptin) Obesity 2009 17 2 349 354
37. Beasley J. M., Ange B. A., Anderson C. A., Miller E. R., Holbrook J. T., Appel L. J., Characteristics associated with fasting appetite hormones (obestatin, Ghrelin, and Leptin) Obesity 2009 17 2 349 354
38. Guo K., McMinn J. E., Ludwig T., Yu Y. H., Yang G., Chen L., Loh D., Li C., Chua S., Zhang Y., Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities Endocrinology 2007 148 8 3987 3997 (Pubitemid 47105835)
39. Dzwonek A. B., Novelli V., Schwenk A., Serum leptin concentrations and fat redistribution in HIV-1-infected children on highly active antiretroviral therapy HIV Medicine 2007 8 7 433 438 (Pubitemid 47335266)
40. Oral E. A., Chan J. L., Rationale for leptin-replacement therapy for severe lipodystrophy Endocrine Practice 2010 16 2 324 333
41. Calmy A., Gayet-Ageron A., Montecucco F., HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial AIDS 2009 23 8 929 939
42. Dzwonek A. B., Novelli V., Schwenk A., Serum leptin concentrations and fat redistribution in HIV-1-infected children on highly active antiretroviral therapy HIV Medicine 2007 8 7 433 438 (Pubitemid 47335266)
43. Hammond E., McKinnon E., Nolan D., Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences Clinical Infectious Diseases 2010 51 5 591 599
44. Schindler K., Haider D., Wolzt M., Rieger A., Gmeinhart B., Luger A., Nowotny P., Ludvik B., Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects European Journal of Clinical Investigation 2006 36 9 640 646 (Pubitemid 44213831)
45. Leitner J. M., Pernerstorfer-Schoen H., Weiss A., Schindler K., Rieger A., Jilma B., Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of highly active antiretroviral therapy (HAART) Atherosclerosis 2006 187 1 177 185 (Pubitemid 43817012)
46. Smith C. C., Yellon D. M., Adipocytokines, cardiovascular pathophysiology and myocardial protection Pharmacology and Therapeutics 2011 129 206 219
47. Falasca K., Ucciferri C., Mancino P., Di Iorio A., Vignale F., Pizzigallo E., Vecchiet J., Cystatin C, adipokines and cardiovascular risk in HIV infected patients Current HIV Research 2010 8 5 405 410
48. Mangge H., Almer G., Truschnig-Wilders M., Schmidt A., Gasser R., Fuchs D., Inflammation, adiponectin, obesity and cardiovascular risk Current Medicinal Chemistry 2010 17 36 4511 4520
49. Cui J., Panse S., Falkner B., The role of adiponectin in metabolic and vascular disease: a review Clinical Nephrology 2011 75 1 26 33
50. Das S., Shahmanesh M., Stolinski M., Shojaee-Moradie F., Jefferson W., Jackson N. C., Cobbold M., Nightingale P., Umpleby A. M., In treatment-nave and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100 Diabetologia 2006 49 3 538 542 (Pubitemid 43277877)
51. Sankale J. L., Tong Q., Hadigan C. M., Tan G., Grinspoon S. K., Kanki P. J., Hotamisligil G. S., Regulation of adiponectin in adipocytes upon exposure to HIV-1 HIV Medicine 2006 7 4 268 274
52. Tong Q., Sankale J. L., Hadigan C. M., Tan G., Rosenberg E. S., Kanki P. J., Grinspoon S. K., Hotamisligil G. S., Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices Journal of Clinical Endocrinology and Metabolism 2003 88 4 1559 1564 (Pubitemid 36623370)
53. Luo L., Zhang L., Tao M., Qiu Z., Xie J., Han Y., Li M., Li T., Adiponectin and leptin levels in Chinese patients with hiv-related lipodystrophy: a 30-month prospective study AIDS Research and Human Retroviruses 2009 25 12 1265 1272
54. Bezante G. P., Briatore L., Rollando D., Maggi D., Setti M., Ghio M., Agosti S., Murdaca G., Balbi M., Barsotti A., Cordera R., Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage Nutrition, Metabolism and Cardiovascular Diseases 2009 19 4 277 282
55. Nogueiras R., Novelle M. G., Vazquez M. J., Lopez M., Dieguez C., Resistin: regulation of food intake, glucose homeostasis and lipid metabolism Endocrine Development 2010 17 175 184
56. Ranade K., Geese W. J., Noor M., Flint O., Tebas P., Mulligan K., Powderly W., Grinspoon S. K., Dube M. P., Genetic analysis implicates resistin in HIV lipodystrophy AIDS 2008 22 13 1561 1568
57. Escote X., Miranda M., Veloso S., Domingo P., Alonso-Villaverde C., Peraire J., Vilades C., Alba V., Olona M., Castro A., Lopez-Dupla M., Sirvent J.-J., Vicente V., Vendrell J., Richart C., Vidal F., Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: implication of resistin Journal of Acquired Immune Deficiency Syndromes 2011 57 1 16 23
58. Jamaluddin M. S., Weakley S. M., Yao Q., Chen C., Resistin: functional roles and therapeutic considerations for cardiovascular disease. British Journal of Pharmacology. In press
59. Cho Y., Lee S. E., Lee H. C., Hur J., Lee S., Youn S. W., Lee J., Lee H. J., Lee T. K., Park J., Hwang S. J., Kwon Y. W., Cho H. J., Oh B. H., Park Y. B., Kim H. S., Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery Journal of the American College of Cardiology 2011 57 1 99 109
60. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I., Cloning and characterization of the cDNA encoding a novel human pre-B- cell colony-enhancing factor Molecular and Cellular Biology 1994 14 2 1431 1437
61. Chang Y. H., Chang D. M., Lin K. C., Shin S. J., Lee Y. J., Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review Diabetes/Metabolism Research and Reviews 2011 27 6 515 527
62. Esteghamati A., Alamdari A., Zandieh A., Elahi S., Khalilzadeh O., Nakhjavani M., Meysamie A., Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity Diabetes Research and Clinical Practice 2011 91 2 154 158
63. Schindler K., Haider D., Wolzt M., Rieger A., Gmeinhart B., Luger A., Nowotny P., Ludvik B., Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects European Journal of Clinical Investigation 2006 36 9 640 646 (Pubitemid 44213831)
64. Kadoglou N. P., Gkontopoulos A., Kapelouzou A., Fotiadis G., Theofilogiannakos E. K., Kottas G., Lampropoulos S., Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study Clinica Chimica Acta 2011 412 1-2 48 52
65. Kadoglou N. P., Sailer N., Moumtzouoglou A., Kapelouzou A., Tsanikidis H., Vitta I., Karkos C., Karayannacos P. E., Gerasimidis T., Liapis C. D., Visfatin (Nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes Experimental and Clinical Endocrinology and Diabetes 2010 118 2 75 80
66. Dahl T. B., Yndestad A., Skjelland M., ie E., Dahl A., Michelsen A., Dams J. K., Tunheim S. H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Froland S. S., Krohg-Sorensen K., Russell D., Aukrust P., Halvorsen B., Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization Circulation 2007 115 8 972 980 (Pubitemid 46328290)
67. Soriguer F., Garrido-Sanchez L., Garcia-Serrano S., Garcia-Almeida J. M., Garcia-Arnes J., Tinahones F. J., Garcia-Fuentes E., Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus Obesity Surgery 2009 19 11 1574 1580
68. Kleinz M. J., Skepper J. N., Davenport A. P., Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells Regulatory Peptides 2005 126 3 233 240 (Pubitemid 40128188)
69. Carpene C., Dray C., Attane C., Valet P., Portillo M. P., Churruca I., Milagro F. I., Castan-Laurell I., Expanding role for the apelin/APJ system in physiopathology Journal of Physiology and Biochemistry 2007 63 4 359 374 (Pubitemid 351492680)
70. Kadoglou N. P., Lampropoulos S., Kapelouzou A., Gkontopoulos A., Theofilogiannakos E. K., Fotiadis G., Kottas G., Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease-KOZANI STUDY Translational Research 2010 155 5 238 246
71. Kuklinska A. M., Sobkowicz B., Sawicki R., Musial W. J., Waszkiewicz E., Bolinska S., Mayszko J., Apelin: a novel marker for the patients with first ST-elevation myocardial infarction Heart and Vessels 2010 25 5 363 367
72. Zou M. X., Liu H. Y., Haraguchi Y., Soda Y., Tatemoto K., Hoshino H., Apelin peptides block the entry of human immunodeficiency virus (HIV) FEBS Letters 2000 473 1 15 18 (Pubitemid 30235176)
73. Puffer B. A., Sharron M., Coughlan C. M., Baribaud F., McManus C. M., Lee B., David J., Price K., Horuk R., Tsang M., Doms R. W., Expression and coreceptor function of APJ for primate immunodeficiency viruses Virology 2000 276 2 435 444
74. Wada J., Vaspin: a novel serpin with insulin-sensitizing effects Expert Opinion on Investigational Drugs 2008 17 3 327 333 (Pubitemid 351578185)
75. Li Q., Chen R., Moriya J., Yamakawa J., Sumino H., Kanda T., Takahashi T., A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity Journal of International Medical Research 2008 36 4 625 629
76. Aust G., Richter O., Rohm S., Kerner C., Hauss J., Klting N., Ruschke K., Kovacs P., Youn B. S., Blher M., Vaspin serum concentrations in patients with carotid stenosis Atherosclerosis 2009 204 1 262 266
77. Tsiodras S., Perelas A., Wanke C., Mantzoros C. S., The HIV-1/HAART associated metabolic syndromenovel adipokines, molecular associations and therapeutic implications Journal of Infection 2010 61 2 101 113